Wird geladen...
Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastoma
BACKGROUND: Pediatric patients with high-risk neuroblastoma (HR NB) often fail to respond to upfront intensive multimodal therapy. Tumor-acquired suppression of apoptosis contributes to therapy resistance. Many HR NB tumors depend on the anti-apoptotic protein Bcl-2 for survival, through Bcl-2 seque...
Gespeichert in:
| Veröffentlicht in: | BMC Cancer |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4752777/ https://ncbi.nlm.nih.gov/pubmed/26874859 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2129-0 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|